

Application No. 10/507,000
Amdt. dated 8 November 2010
Reply to Office Action of 17 August 2010

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-4. (cancelled)

5. (previously presented) The method of claim 9, wherein the active agent is present in a composition selected from pharmaceutical compositions, foodstuffs, food supplements and beverages.

6. (previously presented) The method of claim 9, wherein the active agent is present with one or more additional active agents.

7. (previously presented) The method of claim 6, wherein the one or more additional active agent is selected from, but not limited, to cholinesterase inhibitors, dopamine agonists, COMT inhibitors, MAO-B inhibitors, anti-cholinergics, acetylcholine agonists, serotonin agonists, AMPA receptor agonists, GABA receptor agonists, NMDA receptor agonists, β -adrenoreceptor agonists, digoxin, dobutamine, antiinflammatories, neurotrophic factors, statins, adenosine A2a receptor antagonists, aldose reductase inhibitors, immunomodulators, cannabinoid agonists, interferon β or tricyclic anti-depressants.

8. (cancel)

Application No. 10/507,000
Amdt. dated 8 November 2010
Reply to Office Action of 17 August 2010

9. (currently amended) A method for the treatment of amyotrophic lateral sclerosis (ALS) comprising orally administering to a human or non-human animal in need thereof an effective amount of an active agent in the dosage range of ~~about~~ 0.1 to ~~about~~ 25 mg/kg bodyweight, wherein the active agent is sarsasapogenin.